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Abstract
The evidence-based pharmacotherapy of panic disorder continues to evolve. This paper reviews data on
ﬁrst-line pharmacotherapy, evidence for maintenance treatment, and management options for treatment-
refractory patients. A Medline search of research on pharmacotherapy was undertaken, and a previous
systematic review on the evidence-based pharmacotherapy of panic disorder was updated. Selective
serotonin reuptake inhibitors remain a ﬁrst-line pharmacotherapy of panic disorder, with the serotonin
noradrenaline reuptake inhibitor venlafaxine also an acceptable early option. Temporary co-adminis-
tration of benzodiazepines can be considered. Maintenance treatment reduces relapse rates, but further
research to determine optimal duration is needed. For patients not responding to ﬁrst-line agents several
pharmacotherapy options are available, but there is a notable paucity of data on the optimal choice.
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Introduction
Panic disorder is a common mental disorder that
is associated with signiﬁcant morbidity. Fortunately,
eﬀective treatments for panic disorder are available,
and include both medication and cognitive beha-
vioural therapy (CBT). Ongoing research on the
pharmacotherapy of panic disorder makes it timely to
update an evidence-based approach to the pharma-
cotherapy of panic disorder (Bakker et al. 2005).
Here we brieﬂy emphasize the importance of adequate
care before reviewing the available pharmacological
evidence on treating panic disorder, focusing in
particular on (1) the optimal ﬁrst-line pharmaco-
therapy of panic disorder, (2) the optimal duration
of maintenance therapy, and (3) the optimal approach
to pharmacotherapy in the treatment-refractory
patient. To reveal relevant research conducted in the
past 5 yr (i.e. since the previous review article in
this journal ; Bakker et al. 2005), a Medline search
(2003–2010) using the terms ‘panic’ and ‘treatment’
was undertaken.
Importance of adequate care
Panic disorder is a common mental disorder, with a
12-month prevalence rate of 1.8% (Goodwin et al.
2005). Only a minority of those aﬀected receive
adequate care.
The main reason is that not all patients seek help. It
may take years before individuals with panic disorder
seek help, and only about one third of those aﬀected
seek help within the year of onset (Wang et al. 2005a).
The gap between those aﬀected and those seeking help
for panic disorder is about 50% (Kohn et al. 2004;
Wang et al. 2005b).
When seeking help, individuals with panic disorder
frequently turn to medical specialists or to emergency
units (Hirschfeld, 1996; Katerndahl & Realini, 1995 ;
Leon et al. 1995; Rees et al. 1998; Salvador-Carulla et al.
1995), probably due to the predominance of physical
symptoms. Misdiagnosis by the general practitioner
(Rees et al. 1998) or by the cardiologist at the emerg-
ency unit is common (Harvison et al. 2004; Kuijpers
et al. 2000). Thus, even those who seek help often go
unrecognized.
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Once the correct diagnosis has been made, delivery
of care is often not in concordance with the advice
provided in practice guidelines (Bruce et al. 2003).
It is regrettable that only a minority of individuals
with panic disorder receive evidence-based treatment,
given the unfavourable long-term course of panic
disorder and the impact of panic on daily life. We
brieﬂy discuss these aspects below.
Course
The course of panic disorder in the general population
may be chronic or recurrent (Batelaan et al. 2010a, b ;
Eaton et al. 1998; Kessler et al. 2006; Wittchen et al.
2008). In addition, comorbid disorders tend to develop
during the course of panic disorder (de Graaf et al.
2003; Johnson et al. 1990; Kessler et al. 1998; Wittchen
et al. 2003). Finally, it should be noted that even when
panic symptoms remit, other psychiatric pathology
may be present (Wittchen et al. 2008).
Impact
Panic disorder has a negative impact on well-being
and on health perception (Katerndahl & Realini, 1997;
Klerman et al. 1991), and is associated with impaired
functioning (Kessler et al. 2006; Wittchen et al. 1998)
and absence from work (Alonso et al. 2004; Kouzis &
Eaton, 1994, 1997). In addition, panic disorder may be
associated with suicidal ideation and/or attempts
(Cougle et al. 2009; Goodwin & Roy-Byrne, 2006;
Lepine et al. 1993; Weissman et al. 1989), even if the
impact of comorbid disorders on this association
is a matter of debate (Hornig & McNally, 1995) and
although the evidence that panic disorder causes
suicidality remains unclear (Sareen et al. 2005a). Panic
disorder is also associated with medical morbidity,
including cardiovascular disease (Chen et al. 2009;
Gomez-Caminero et al. 2005; Sareen et al. 2005b ;
Smoller et al. 2007). Some studies report increased
mortality rates in individuals with panic disorder as a
result of suicide (Coryell et al. 1982) or cardiovascular
disease (Coryell et al. 1982; Grasbeck et al. 1996;
Smoller et al. 2007). Finally, panic disorder causes
considerable economic costs to society, compared to
healthy persons and to other psychiatric disorders
(Andlin-Sobocki & Wittchen, 2005; Batelaan et al.
2007; Salvador-Carulla et al. 1995).
Available pharmacological evidence
Pharmacological agents with suﬃcient evidence to
support their use in the treatment of panic disorder
include antidepressants [the selective serotonin
reuptake inhibitors (SSRIs), the serotonin nora-
drenaline reuptake inhibitor (SNRI) venlafaxine,
several tricyclic antidepressants (TCAs) and the ir-
reversible MAO inhibitor (MAOI) phenelzine], and
benzodiazepines. First, we review antidepressants
and benzodiazepines with regard to eﬃcacy in acute
and long-term treatment, the side-eﬀects and risks
involved, drop-out rates, onset of action and eﬃcacy
in comorbid conditions. This comparison will be used
to determine which agents should be considered
ﬁrst-line treatments. Next we review data on optimal
duration of maintenance therapy and optimal ap-
proach to pharmacotherapy of treatment-refractory
patients.
Antidepressants
Eﬃcacy in acute phase treatment
Antidepressants acting on the serotonergic system
are eﬀective in treating panic disorder. These include
the SSRIs (citalopram, ﬂuvoxamine, ﬂuoxetine,
paroxetine, sertraline) (Bakker et al. 2002; Hoehn-Saric
et al. 1993; Lecrubier et al. 1997; Michelson et al. 1998;
Pollack et al. 1998; Stahl et al. 2003; Wade et al. 1997),
the TCAs imipramine and clomipramine (CNCPS,
1992 ; Papp et al. 1997), the SNRI venlafaxine (Bradwejn
et al. 2005; Liebowitz et al. 2009; Pollack et al. 2007a, b),
and the irreversible MAOI phenelzine (Sheehan et al.
1980; Tyrer et al. 1973).
During the past few years the SSRIs paroxetine
controlled-release formulation (paroxetine CR) and
escitalopram, and the SNRI venlafaxine extended-
release (venlafaxine XR) have been thoroughly in-
vestigated in panic disorder. Three double-blind
placebo-controlled trials investigating paroxetine CR
were pooled, allowing analysis of a total study popu-
lation of 889 panic disorder patients. Paroxetine CR
(25–75 mg/d) was superior to placebo on the primary
outcome measure, percentage of patients who were
free of panic attacks in the 2 wk prior to endpoint
(Sheehan et al. 2005). In a 10-wk randomized con-
trolled, double-blind trial (total n=366, n=128 with
escitalopram), escitalopram (5–10 mg/d) was more
eﬀective than placebo (Stahl et al. 2003). Finally, the
SNRI venlafaxine XR (75–225 mg/d) has been found
signiﬁcantly more eﬀective than placebo in several
randomized controlled, double-blind trials (Bradwejn
et al. 2005; Liebowitz et al. 2009; Pollack et al. 2007a, b ;
for an overview see Kjernisted & McIntosh, 2007).
The daily dosages of these antidepressants when used
for panic disorder are similar to those used for major
depressive disorder (see Table 1).
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Eﬃcacy in long-term treatment
The SSRIs (i.e. citalopram, ﬂuvoxamine, paroxetine)
(Holland et al. 1994; Lecrubier & Judge, 1997 ; Lepola
et al. 1998) and the TCAs (Curtis et al. 1993; Lecrubier
& Judge, 1997; Mavissakalian & Perel, 1992) all remain
eﬀective in the treatment of panic disorder over the
long-term (follow-up periods up to 2 yr). Recently,
a 6-month placebo-controlled discontinuation study
found that time to relapse was signiﬁcantly longer
in the venlafaxine XR group than the placebo group
(Ferguson et al. 2007). No studies investigating the
long-term eﬃcacy of phenelzine have been conducted.
Side-eﬀects and risks involved
Side-eﬀects of antidepressants diﬀer partly across
various classes of antidepressants (APA, 2009).
The most common side-eﬀects of the SSRIs include
headaches, irritability, gastrointestinal complaints,
insomnia, sexual dysfunction, weight gain, increased
anxiety, drowsiness and tremor. The most common
side-eﬀects of venlafaxine as reported in panic dis-
order patients are nausea, dry mouth, constipation,
anorexia, insomnia, sweating, somnolence, tremor and
sexual dysfunction. Monitoring of blood pressure is
advised given the increase in blood pressure that
is sometimes observed. In TCAs the most commonly
reported side-eﬀects in panic disorder patients are
anticholinergic eﬀects, increased sweating, sleep dis-
turbance, orthostatic hypotension and dizziness, fa-
tigue and weakness, cognitive disturbance, weight
gain, and sexual dysfunction. Speciﬁc concern is
needed when treating elderly patients with TCAs as
orthostatic hypotension may result in falls. In ad-
dition, arrhythmias may occur in patients with pre-
existing cardiac conduction abnormalities, and in case
of an overdose. The irreversible MAOI phenelzine has
an unfavourable side-eﬀect proﬁle, including hypo-
tension, weight gain, sexual dysfunction, paresthesia,
myoclonic jerks, dry mouth, oedema and sleeping
problems. Probably more important, to avoid life-
threatening hypertensive crisis, adherence to a strict
low tyramine diet is required (Rosenberg, 1999).
To prevent side-eﬀects, it is advised to start treat-
ment with antidepressants at a low dosage. Of special
importance is the ﬁnding that panic symptoms often
increase in the ﬁrst weeks of treatment with SSRIs,
venlafaxine or TCAs. This may be partly due to mis-
interpreting physical side-eﬀects as symptoms of a
panic attack. Psycho-education should aim to prevent
such misinterpretations, and slow dose titration is
recommended. To lower anxiety symptoms and to
achieve a more rapid stabilization of panic symptoms,
temporary addition of benzodiazepines during the
initial phase of antidepressant treatment can also be
considered (Goddard et al. 2001; Pollack et al. 2003).
Drop-out rates
During SSRI treatment of panic disorder 18% of
patients drop-out prematurely (Bakker et al. 2002). The
recently investigated agents paroxetine CR, escitalo-
pram, and venlafaxine are all well tolerated in panic
disorder patients, and hence, reported drop-out rates
were relatively low: 11% of patients treated with
paroxetine CR (Sheehan et al. 2005), 6.3% of patients
treated with escitalopram (Stahl et al. 2003) and 1–12%
of patients treated with venlafaxine (Kjernisted &
McIntosh, 2007). With TCAs, about 30% of patients
drop-out of treatment (Bakker et al. 2002). Due to the
unfavourable side-eﬀect proﬁle of MAOIs, drop-out
rates are high.
Onset of action
For all antidepressants, onset of action in panic dis-
order is relatively slow. As a result, an assessment of
outcome should be made only after several weeks of
treatment.
Table 1. Dosage of drugs eﬀective in panic disorder
(mg/day)
Drug name Start Mean Maximum
Antidepressants
SSRIs
Citalopram 10 20–30 60
Escitalopram 5 10 20
Fluoxetine 20 20 60
Fluvoxamine 50 100–150 300
Paroxetine 10 20–40 60
Sertraline 50 100 200
SNRIs
Venlafaxine 37.5 75–150 225
TCAs
Clomipramine 25 100–150 250
Impiramine 25 100–150 300
Benzodiazepines
Alprazolam 1.5 4–6 –a
Clonazepam 1 2–3 –a
Diazepam 5–10 40–50 –a
Lorazepam 1 2–4 –a
MAOIs
Phenelzine 10 40–60 –a
a Only use mean dosage.
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Eﬃcacy in comorbid conditions
Antidepressants are eﬀective for a range of anxiety
disorders and depressive disorder, which are com-
monly comorbid with panic disorder (Bandelow et al.
2008).
Benzodiazepines
Eﬃcacy in acute phase treatment
The benzodiazepines alprazolam, clonazepam, diaz-
epam and lorazepam are superior to placebo in the
acute phase treatment of panic disorder (CNCPS,
1992 ; Van Balkom et al. 1995, 1997). The mean dosages
of benzodiazepines used in acute treatment are
provided in Table 1.
Eﬃcacy in long-term treatment
Controlled studies up to 32 wk with alprazolam
(Ballenger, 1991 ; Burrows et al. 1993), and an open
study with clonazepam lasting over 1 yr (Pollack et al.
1986) showed that these benzodiazepines are eﬃca-
cious in maintenance treatment. Sometimes the daily
dosage could be reduced while remaining eﬃcacious.
Side-eﬀects and risks involved
Side-eﬀects of benzodiazepines include sedation, fati-
gue, ataxia, slurred speech, memory impairment, and
weakness (APA, 2009). Usually, treatment is started at
a low dose to diminish side-eﬀects. Caution is advised
in prescribing benzodiazepines for elderly patients
because of a higher risk of falls, and for patients
driving vehicles because of a higher risk of motor
vehicle accidents. When prescribed for long-term use,
dependence may occur. Hypothetically, this may
have two adverse consequences : dose escalation and
problems withdrawing the medication. While dose
escalation does not appear a common consequence of
long-term benzodiazepine use, problems when dis-
continuing benzodiazepines are frequently reported,
especially during the last half of the taper period
(APA, 2009).
Drop-out rates
In panic disorder trials, drop-out rates due to side-
eﬀects are about 15% for benzodiazepines (LSMRG,
2009).
Onset of action
Benzodiazepines have a fast onset of action, i.e.
they produce eﬀects as soon as an eﬀective dose is
administered (Burrows & Norman, 1999).
Eﬃcacy in comorbid conditions
Benzodiazepines are generally thought ineﬀective for
comorbid depressive disorders (Bandelow et al. 2008).
Optimal ﬁrst-line pharmacotherapy
With regard to eﬃcacy in acute treatment, comparable
eﬃcacy has been revealed when directly comparing
antidepressants (imipramine) and benzodiazepines
(alprazolam, clonazepam) (Van Balkom et al. 1995),
SSRIs and TCAs (Bakker et al. 1999, 2002; Lecrubier
et al. 1997; Otto et al. 2001; Wade et al. 1997), and when
comparing various SSRIs (Dannon et al. 2007). In one
study, a high dosage of venlafaxine (225 mg) proved to
be superior to 40 mg paroxetine on the primary out-
come measure (percentage of patients free from full-
symptom panic attacks) and on one of the secondary
outcome measures (improvement on the Panic
Disorder Severity Scale) (Pollack et al. 2007a). In panic
disorder, only one trial administered either escitalo-
pram, citalopram or placebo. However, in this trial no
direct comparisons between escitalopram and citalo-
pram were made (Stahl et al. 2003). As described
above, both antidepressants (SSRIs, SNRI venlafaxine,
TCAs) and benzodiazepines remain eﬀective over the
long term.
Given the comparable eﬃcacy of the pharmaco-
logical classes described above in acute-phase treat-
ment and the eﬃcacy in long-term treatment, other
considerations determine which agent should be
considered the ﬁrst-line pharmacotherapy of panic
disorder. These include side-eﬀects and risks in-
volved, drop-out rates, the time of onset of action, and
eﬃcacy in comorbid symptomatology.
Considering these aspects, SSRIs and venlafaxine
should both be considered ﬁrst-line agents. Given the
slow onset of action and the potential for increased
anxiety during the initial phase of treatment with
antidepressants, temporary co-administration of a
benzodiazepine should be considered. SSRIs and
venlafaxine are eﬀective in acute and long-term treat-
ment, have an acceptable side-eﬀect proﬁle, acceptable
drop-out rate, and are eﬀective in comorbid de-
pression. Direct comparisons between SSRIs and ven-
lafaxine with regard to onset of action, side-eﬀect
proﬁle or drop-out rates have not been made in panic
disorder. Similarly, direct comparisons of the toler-
ability proﬁle and onset of action of recently investi-
gated agents (paroxetine CR, escitalopram) and other
SSRIs are lacking.
TCAs may have a slower onset than SSRIs
(Lecrubier et al. 1997). In addition, TCAs have a less
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tolerable side-eﬀect proﬁle than SSRIs given that they
have more anticholinergic eﬀects, and are generally
less safe than SSRIs. Finally, reported drop-out rates
are higher for TCAs compared to SSRIs (Bakker et al.
2002).
Benzodiazepines have a faster onset of action and
lower drop-out rates compared to TCAs (Van Balkom
et al. 1995). The tolerability of benzodiazepines is
usually good, but patients may suﬀer from drowsiness
and cognitive side-eﬀects. Another disadvantage
is that these drugs may lead to benzodiazepine de-
pendence. Moreover, benzodiazepines are generally
thought ineﬀective with regard to comorbid psycho-
pathology such as depressive disorders, whereas
antidepressants are not (Bandelow et al. 2008). This
is of importance, because depressive disorders often
complicate panic disorder (Ravelli et al. 1998). In
summary, benzodiazepines as monotherapy should
not be regarded as a ﬁrst-line treatment in view of
their side-eﬀect proﬁle (which includes dependence)
and in view of their lack of eﬃcacy in treating
comorbid conditions.
The irreversible MAOI phenelzine should be pre-
scribed only in case of severe and treatment-refractory
panic disorder given the side-eﬀect proﬁle and risks
involved, and the high drop-out rates.
Optimal duration of pharmacotherapy
Considering the long-lasting, often relapsing course of
panic disorder, optimizing the long-term outcome and
thus reducing the vulnerability to relapse should be
a main goal of treatment (Andrews, 2003 ; Batelaan
et al. 2010a ; Fava & Mangelli, 1999). Discontinuation
of pharmacotherapy frequently results in relapse
(Ferguson et al. 2007; Lecrubier & Judge, 1997 ; Lotufo-
Neto et al. 2001; Marks et al. 1993; Mavissakalian &
Perel, 1999; Noyes et al. 1989, 1991 ; Rapaport et al.
2001; Spiegel et al. 1994). For example, 37% of patients
experienced a relapse within 10 wk of discontinuing
clomipramine, and another 43% of patients within
about 112 yr (Lotufo-Neto et al. 2001), over one third
relapsed within the ﬁrst year of imipramine dis-
continuation (Mavissakalian & Perel, 1999), and half of
those who discontinued venlafaxine relapsed within
6 months (Ferguson et al. 2007).
The consistent ﬁnding that maintenance pharma-
cotherapy may prevent relapse when compared to
medication discontinuation (Donovan et al. 2010) can
be considered an argument to continue pharmaco-
therapy for a longer period. Another argument for
continuing pharmacotherapy is that during mainten-
ance treatment, further improvements can be seen
(Ballenger, 2000 ; Lecrubier & Judge, 1997). However,
many remitted patients discontinue antidepressant
treatment. Studies investigating treatment adherence
of anxiety disorder patients and, more speciﬁcally of
panic disorder patients, reported that more than half
of the patients are non-compliant or interrupt treat-
ment within several months to years (Stein et al. 2006;
Toni et al. 2004).
A crucial question is what is the optimal duration of
pharmacotherapy that will allow patients to discon-
tinue pharmacotherapy relatively safely (i.e. without a
substantial risk for relapse), and not take medication
longer than necessary. Research with regard to the
optimum duration of pharmacotherapy is sparse ;
however, results so far do not indicate the existence of
a ‘safe’ period to withdraw from medication. In a
study conducted by Mavissakalian & Perel, (2002)
the duration of treatment with imipramine following
response was not associated with relapse : relapse
occurred as frequently after 6 months of treatment as
it did after 12–30 months of treatment (Mavissakalian
& Perel, 2002). In addition, Choy and colleagues
reported that even after 3 yr of sustained remission
while taking medication, relapse occurs more often
and earlier in those who discontinue medication
compared to those who continue pharmacological
treatment (Choy et al. 2007). However, because this is
a naturalistic study, a ﬁrm causal relation cannot be
presumed.
Given the limited empirical data available, inter-
national guidelines diﬀer slightly in their recom-
mendations on maintenance treatment. Whereas the
guideline from the American Psychiatric Association
refrains from recommendations (APA, 2009), most
guidelines refer to expert consensus and suggest con-
tinuation for at least a year (Andrews, 2003 ; Bandelow
et al. 2008; LSMRG, 2009), although a shorter period
has also been suggested (Baldwin et al. 2005; CPA,
2006).
When medication is being discontinued, consensus
advice is to taper down the medication gradually
over weeks to months (APA, 2009; Andrews, 2003 ;
Baldwin et al. 2005; LSMRG, 2009) to reduce the like-
lihood of discontinuation symptoms and to monitor
for early signs of relapse.
To reduce the risk for relapse and optimize the
long-term outcome in panic disorder, research on
the optimal duration of pharmacotherapy should be
conducted, as well as research on how to optimize
treatment adherence. In addition, other lines of
research may also be fruitful.
First, predictors for relapse should be identiﬁed,
because those at the highest risk for relapse may
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beneﬁt most from long-term maintenance treatment,
and it can be hypothesized that patients at the highest
risk for relapse are better motivated for long-term
maintenance treatment. In addition, costs of long-
term maintenance treatment for those at highest risk
to relapse may well be acceptable given the costs
associated with recurrence of panic disorder.
Second, the question of whether maintenance treat-
ment with lower dosages will suﬃce to maintain
acute-phase improvements is worthy of further study,
given previous results of a small study in which
patients maintained their improvement when imipra-
mine was continued at half the dosage (Mavissakalian
& Perel, 1992), and studies indicating that the daily
dosage of benzodiazepines can be reduced while
remaining eﬃcacious (Ballenger, 1991 ; Burrows et al.
1993; Pollack et al. 1986).
Third, providing psychotherapy to panic disorder
patients may also be beneﬁcial in enhancing the long-
term outcome for several reasons, the most important
reason being that the eﬀects of CBT may be main-
tained over time (Bakker et al. 1998; Fava et al. 2001;
Oei et al. 1999; Peter et al. 2008). In addition, some
evidence indicates that a CBT relapse-prevention
programme provided after acute-phase treatment
prevents relapse in patients with panic disorder
(Wright et al. 2000) and that adding brief psycho-
dynamic psychotherapy to clomipramine treatment
may reduce relapse rates in panic disorder (Wiborg &
Dahl, 1996). Finally, a few studies have shown that
CBTmay also prevent relapse or worsening of panic in
patients who discontinue pharmacological treatment
(Bruce et al. 1999; Choy et al. 2007; Furukawa et al.
2007; Schmidt et al. 2002; Spiegel et al. 1994; Whittal
et al. 2001).
Optimal approach to pharmacotherapy in
treatment-refractory patients
Despite the availability of treatments with reported
eﬃcacy, a substantial number of panic disorder
patients do not respond, or only respond partially to
treatment. For example, Pollack et al. (2007b) reported
response rates between 70% and 80% and remission
rates around 45% during the acute treatment of panic
disorder with venlafaxine, thereby underscoring the
need for additional treatment strategies to achieve full
remission. There are, however, few data to guide
clinicians in next-step treatment strategies (Ipser et al.
2006). The approach to treatment-refractory patients
may consist of optimizing the current treatment,
switching to another agent or treatment modality, or
augmentation.
Optimizing treatment
With regard to optimizing the current pharmaco-
therapy, it may be useful to investigate whether the
patient is adhering to the treatment regimen, given the
high rates of non-compliance with pharmacological
treatment. In addition, it should be noted that during
maintenance treatment, further improvements may
occur (Ballenger, 2000 ; Lecrubier & Judge, 1997).
With regard to the dosage, assessing the blood level in
imipramine treatmemt may be helpful (Mavissakalian
& Perel, 1995). By contrast, a small study reported
that an increased dosage of a SSRI was no more
eﬀective than continuing the previous dosage (Simon
et al. 2009b), a ﬁnding that is in line with recent
research on the absence of additional eﬀects when
increasing the SSRI dose in depressed patients (Ruhe
et al. 2009).
Switching
Switching within or between classes of pharmaco-
logical agents seems a reasonable option. Based on
safety and tolerability issues described above, we
propose the following steps : SSRI or venlafaxine,
another SSRI or venlafaxine, clomipramine or imipra-
mine, benzodiazepine, MAOI. Switching to another
treatment modality with proven eﬃcacy in treating
panic disorder, such as CBT, is also a reasonable
option. CBT is eﬀective in panic disorder (Furukawa
et al. 2007), and positive eﬀects have been reported for
CBT in studies with panic disorder patients who failed
to respond adequately to pharmacological treatment
(Rodrigues et al. 2011).
In addition, a wide range of other pharmacological
agents has been suggested for the treatment of panic
disorder. These include SNRIs other than venlafaxine
(Blaya et al. 2007; Simon et al. 2009a), the selective
noradrenergic reuptake inhibitor reboxetine (Bertani
et al. 2004; Dannon et al. 2002; Seedat et al. 2003;
Versiani et al. 2002), GABAergic treatment including
vigabatrin and tiagabine (Pande et al. 2000; Zwanzger
& Rupprecht, 2005 ; Zwanzger et al. 2009a), the re-
versible MAOI moclobemide (Kruger & Dahl, 1999;
Loerch et al. 1999; Ross et al. 2010; Tiller et al. 1999;
Uhlenhuth et al. 2002), other antidepressants including
mirtazapine, buproprion, trazodone (APA, 2009), anti-
convulsants (Mula et al. 2007; Papp, 2006), the
antipsychotic olanzapine (Holliﬁeld et al. 2005), and
antihypertensives (APA, 2009). None of these agents
can be considered as ﬁrst-line options for the phar-
macological treatment of panic disorder because they
are insuﬃciently investigated or because results were
inconsistent. To determine their role in treating panic
408 N. M. Batelaan et al.
disorder, randomized controlled trials of suﬃcient
sample sizes are needed to verify results and to
compare both eﬃcacy and tolerability with more
established treatments. A clinician could potentially
consider prescribing these agents in treatment-
refractory patients, prioritizing those agents for which
there is the most data on eﬃcacy and tolerability.
The agents for which there is most data on eﬃcacy
and tolerability are the SNRIs milnacipran and
duloxetine and the selective noradrenergic reuptake
inhibitor reboxetine. This is not surprising given the
eﬃcacy of the SNRI venlafaxine in the treatment of
panic disorder and the noradrenergic role in the
pathophysiology of panic disorder. Small open-label
studies showed positive results for the SNRIs milna-
cipran (Blaya et al. 2007) and duloxetine (Simon et al.
2009a). Reboxetine has been investigated in several
small studies. In a single-blind, cross-over study,
reboxetine was as eﬀective as citalopram with regard
to panic, although less eﬀective than citalopram with
regard to co-occurring depressive symptoms (Seedat
et al. 2003). In a single-blind randomized trial (n=68),
paroxetine showed larger eﬀects on panic attacks than
reboxetine, but no diﬀerences were found on antici-
patory anxiety and avoidance (Bertani et al. 2004). In a
double-blind randomized, controlled trial reboxetine
was more eﬀective compared to a placebo group
(Versiani et al. 2002). Finally, in a small open-label
study, reboxetine showed positive eﬀects for patients
who had not responded to a SSRI (Dannon et al. 2002).
Given these preliminary results, both these SNRIs
and reboxetine might be an option when prescribing
oﬀ-label agents in treatment-refractory patients.
Other treatment modalities with insuﬃcient evi-
dence to date can also be considered in treatment-
refractory patients. It should be stressed that, given the
design and size of the studies, these results should
be viewed as preliminary. Risk-beneﬁt ratios should
be taken into account. Options include repetitive
transcranial magnetic stimulation and aerobic exer-
cise. Repetitive transcranial magnetic stimulation has
shown some beneﬁcial eﬀects for panic disorder in
several small and open studies (Pigot et al. 2008;
Zwanzger et al. 2009b). With regard to aerobic exer-
cise, it was found that subsequent to exercise, panic
disorder patients had less frequent panic when chal-
lenged with carbon dioxide (Esquivel et al. 2008) or
cholecystokonin tetrapeptide (CCK-4) compared to
controls who had no exercise or only very light exer-
cise (Strohle et al. 2009). In an earlier study aerobic
exercise indeed reduced panic symptoms, but later
and less eﬀectively than medication (Broocks et al.
1998). Results of a recent randomized controlled trial
of aerobic exercise in panic disorder patients were
disappointing (Wedekind et al. 2010).
Augmentation
Pharmacological treatment can be augmented by the
use of additional medications, or by other treatment
modalities. The incremental eﬃcacy of combined
psychotherapy (most often CBT) and antidepressant
treatment was investigated in a Cochrane review in-
cluding 21 trials in panic disorder (Furukawa et al.
2007). The authors concluded that in the short term,
combined therapy was superior to medication alone,
as well as to psychotherapy alone. These ﬁndings were
irrespective of the kind of antidepressant (TCA vs.
SSRI), irrespective of the presence of agoraphobia, and
irrespective of the presence of comorbid depression.
Six months after terminating treatment, combination
therapy was more eﬀective than medication alone, but
was as eﬀective as psychotherapy alone. This ﬁnding
should be interpreted with some caution, given the
naturalistic nature of the follow-up period, with a
substantial proportion of patients receiving treatment
of some kind (Furukawa et al. 2007). Insuﬃcient data
are available to determine whether combining benzo-
diazepines and psychotherapy is beneﬁcial or not
(Watanabe et al. 2007).
Augmenting benzodiazepines to antidepressant
treatment is an option as this appeared equally
eﬀective compared to adding CBT to antidepressants
in panic disorder. However, it should be noted that
eﬀects of both strategies were small in this study
(Simon et al. 2009b). In addition, augmentation of
antidepressants with an antipsychotic has been sug-
gested for refractory panic disorder patients (Hoge
et al. 2008; Saito & Miyaoka, 2007 ; Sepede et al. 2006;
Simon et al. 2006). Risk-beneﬁt ratios should be care-
fully considered given the adverse eﬀects of anti-
psychotics. D-cycloserine, a partial agonist of the
N-methyl-D-aspartate glutamergic receptor, has re-
cently received attention because it may enhance fear
extinction during exposure therapy (Hofmann, 2007).
A small (n=31) randomized, double-blind, placebo-
controlled trial in which interoceptive exposure was
augmented with either low doses of D-cycloserine
or placebo showed that panic disorder patients who
received D-cycloserine had better outcomes, both at
post-treatment, and at 1-month follow-up (Otto et al.
2010).
Conclusion
Panic disorder is a prevalent and disabling disorder
that can be treated eﬀectively. However, only a
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minority of those suﬀering from panic disorder appear
to be adequately treated. The ﬁrst-line pharmacother-
apy for panic disorder has been SSRIs for some time,
and there is now suﬃcient evidence to indicate that
the SNRI venlafaxine should also be considered as a
ﬁrst-line agent. Less is known about how improve-
ments can be maintained and how relapses can be
prevented in patients who have responded well to
medication in the acute phase. In general, however,
most treatment recommendations are conservative,
advising at least a year of antidepressant treatment.
Similarly, relatively little is known about how
best to manage treatment-refractory panic disorder.
Nevertheless, current options include a range of
switching and augmentation strategies. Further re-
search comparing these options is needed.
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